{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-077373","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.880726+00:00","generated_at":"2026-05-20T10:17:48.725622+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026","bullets":["Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.","LUCIA trial 60% randomized; enrollment completion expected Q3 2025.","Topline 56-week LUGANO data mid-2026; LUCIA data in H2 2026.","Phase 3 trials are randomized, double-masked, non-inferiority vs. aflibercept; DURAVYU dosed every 6 months.","DURAVYU is sustained-delivery vorolanib (TKI); potential first sustained-release TKI for wet AMD."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-077373","json":"https://secwatch.observer/filing/0000950170-25-077373.json","markdown":"https://secwatch.observer/filing/0000950170-25-077373.md","text":"https://secwatch.observer/filing/0000950170-25-077373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/0000950170-25-077373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/eypt-20250527.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:17:48.725622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}